Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

Similar documents
Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

COME HOME Innovative Oncology Business Solutions, Inc.

亞東紀念醫院 Breast Cancer 化學治療處方集

Chapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Breast Cancer Breast Managed Clinical Network

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

It is a malignancy originating from breast tissue

Clinical Management Guideline for Breast Cancer

Triple Negative Breast Cancer: Part 2 A Medical Update

See Important Reminder at the end of this policy for important regulatory and legal information.

Disease Update: Metastatic Breast Cancer

Adjuvant Chemotherapy + Trastuzumab

新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy

Nadia Harbeck Breast Center University of Cologne, Germany

TRANSPARENCY COMMITTEE OPINION. 15 February 2006

Working Formulary January 2013 Oncology Chemotherapy Regimens

Perjeta (pertuzumab)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy

HER2-positive Breast Cancer

See Important Reminder at the end of this policy for important regulatory and legal information.

Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer

Breast Cancer Clinical Trials in Georgia

Horizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887

See Important Reminder at the end of this policy for important regulatory and legal information.

Therapy Side Effects

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA

METASTATIC BREAST CANCER: CONTROLLING THE HERD WHEN THE HORSES ARE OUT OF THE BARN

Clinical Expert Submission Template

Systemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven

Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment

Highlights. Padova,

Breast Cancer Clinical Pathway Committee Development Meeting

BREAST CANCER (RECURRENT OR METASTATIC) TREATMENT REGIMENS (Part 1 of 5)

Metastatic Breast Cancer What is new? Subtypes and variation?

Breast cancer. Prof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA

Haematology, Oncology and Palliative Care Directorate.

乳癌化療指引. Breast Cancer

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source

Supplementary appendix

Treatment of HER-2 positive breast cancer

National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007

癌症診療指引175 Chemotherapy regimens for primary or adjuvant therapy

Non-Anthracycline Adjuvant Therapy: When to Use?

Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance


乳癌化療指引. 104 年 12 月第六版 年,1 st - 5 th 版

PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES

Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon

Breast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.

Toxicities of Chemotherapy Regimens used in Early Breast Cancer

TRANSPARENCY COMMITTEE OPINION. 29 April 2009

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient

Locally Advanced Breast Cancer: Systemic and Local Therapy

RECENT ADVANCES BREAST CANCER THERAPY. Bhanu Priya B, 2 Basavanna P L, 1 Postgraduate, 2 Professor Department of Pharmacology, MMC&RI, Mysore

Immunoconjugates in Both the Adjuvant and Metastatic Setting

Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer

Locally Advanced Breast Cancer: Systemic and Local Therapy

ASCO 2017 BREAST CANCER HIGHLIGHTS

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Oncological Treatment of Breast Cancer

CCC Chemotherapy Protocols V9.0

Clinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94

Thames Valley. Thames Valley Chemotherapy Regimens Breast Cancer

Supplementary Online Content

Use of Taxanes in Older Breast Cancer Patients

ASCO and San Antonio Updates

The Pharmacist s Role in Breast Cancer Awareness and Treatment

Breast Cancer: Chemotherapy and Novel Agents

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

Breast Cancer. Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy

Standard Breast Cancer Therapy

Treatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London

Chemotherapy as Primary or Adjuvant Therapy (HER2-POSTIVE)

PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid

Novel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial

Review Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer Sara López-Tarruella and Miguel Martín

NeoadjuvantTreatment In BC When, How, Who?

MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014

Etudes cliniques Service d Oncologie - Radiothérapie

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,

Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer

Supplementary Online Content

Adjuvant Chemotherapy TNBC & HER2 Subtype

Advances in the Management. of Breast Cancer

MASCC Guidelines for Antiemetic control: An update

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

Treating Advanced Breast Cancer in the Older Woman

Breast Cancer. Breast Cancer. Established breast cancer risk factors. Established breast cancer risk factors. Cancer incidence.

Guidelines for the Use of Anti-Emetics with Chemotherapy

Transcription:

Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles fluorouracil 600 mg/m 2 CMF oral cyclophosphamide 100 mg/m 2 po daily for 14 days every 4 weeks x 6 cycles methotrexate 40 mg/m 2 days 1 & 8 fluorouracil 600 mg/m 2 days 1 & 8 Docetaxel Carboplatin with Trastuzumab (TCH) docetaxel 75 mg/m 2 IV day 1 every 3 weeks x 6 cycles carboplatin AUC = 6 IV day 1 8 mg/kg IV cycle 1 (LD); then, 6mg/kg (MD) for cycles 2 to 6 Docetaxel Cyclophosphamide (TC) docetaxel 75 mg/m 2 IV day 1 every 3 weeks x 4 cycles cyclophosphamide 600 mg/m 2 IV day 1 Docetaxel Cyclophosphamide with Trastuzumab (TC plus H) docetaxel 75 mg/m 2 IV day 1 every 3 weeks x 4 cycles cyclophosphamide 600 mg/m 2 IV day 1 8 mg/kg IV cycle 1 (LD); then, 6mg/kg (MD) for cycles 2 to 4 FE 100C fluorouracil 500 mg/m 2 IV day 1 every 3 weeks x 6 cycles epirubicin 100 mg/m 2 IV day 1 cyclophosphamide 500 mg/m 2 IV day 1

FEC-Doc fluoruouracil 500 mg/m 2 IV day 1 every 3 weeks x 3 cycles epriubicin 100 mg/m 2 IV day 1 cyclophosphamide 500 mg/m 2 IV day 1 -followed bydocetaxel 100mg/m 2 IV day 1 every 3 weeks x 3 cycles FEC-Doc with Trastuzumab as per FEC-Doc plus 8mg/kg (LD) with cycle 1 of docetaxel; followed by 6 mg/kg (MD) for the next 2 cycles AC-T AC x 4 cycles followed by.. paclitaxel 80 mg/m 2 IV day1 weekly x 12 weeks AC-T + Trastuzumab AC-T with starting concurrently with paclitaxel 4 mg/kg cycle1 (LD); then, 2 mg/kg (MD) for cycles 2-12, then as per maintenance Trastuzumab (maintenance) following chemotherapy, is to continue to a maximum of 1 year (equivalent of 18 doses given every 3 weeks) over a maximum of 14 months from the 1 st dose of.

Adjuvant Hormonal Therapy:

Neoadjuvant Regimens AC x 4 Doc x 4 4 cycles of AC followed by 4 cycles of docetaxel 100 mg/m 2 every 3 weeks Docetaxel carboplatin with docetaxel 75 mg/m 2 IV day 1 every 3 weeks x 6 cycles carboplatin AUC = 6 8 mg/kg (LD) cycle 1; 6 mg/kg (MD) cycles 2-6 FEC x 4 Doc x 4 4 cycles of FEC followed by 4 cycles of docetaxel 100 mg/m 2 every 3 weeks If patients are HER2 positive and physician chooses either AC x 4 Doc x 4 or FEC x 4 Doc x 4, the would start with the first cycle of docetaxel at 8 mg/kg for cycle 1 of docetaxel and then 6 mg/kg for subsequent cycles of docetaxel. Paclitaxel-Carboplatin weekly with paclitaxel 80 mg/m 2 IV days 1, 8 & 15 every 4 weeks x 4-6 cycles carboplatin AUC = 2 IV days 1, 8 & 15 4 mg/kg (1 st dose); followed by 2 mg/kg weekly continuously Trastuzumab (maintenance) following chemotherapy, is to continue to a maximum of 1 year (equivalent of 18 doses given every 3 weeks) over a maximum of 14 months from the 1 st dose of.

Appendix: 4 Metastatic Regimens Abraxane nab-paclitaxel 260 mg/m 2 IV every 3 weeks AC doxorubin 60 mg/m 2 every 3 weeks x 4-6 cycles Cyclophosphamide 600 mg/m 2 Capecitabine 1000 mg/m 2 po bid x 14 days every 3 weeks CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 fluorouracil 600 mg/m 2 CMF oral cyclophosphamide 100 mg/m 2 po daily for 14 days every 4 weeks methotrexate 40 mg/m 2 days 1 & 8 fluorouracil 600 mg/m 2 days 1 & 8 Docetaxel Carboplatin with Trastuzumab docetaxel 75 mg/m 2 IV day 1 every 3 weeks carboplatin AUC = 6 IV day 1 Docetaxel Cyclophosphamide docetaxel 75 mg/m 2 IV day 1 every 3 weeks x 4 cycles cyclophosphamide 600 mg/m 2 IV day 1 Docetaxel Cyclophosphamide with Trastuzumab docetaxel 75 mg/m 2 IV day 1 every 3 weeks cyclophosphamide 600 mg/m 2 IV day 1

Docetaxel with docetaxel 100 mg/m 2 IV day 1 every 3 weeks Docetaxel 100 mg/m 2 IV day 1 every 3 weeks Docetaxel (weekly) 35 mg/m 2 IV days 1,8 &15 every 4 weeks Docetaxel weekly with docetaxel 35 mg/m 2 IV days 1,8 &15 every 4 weeks 4 mg/kg (1 st dose); followed by 2 mg/kg weekly continuously OR 8 mg/kg (1 st dose); followed by 6 mg/kg every 3 weeks Doxorubicin 60 mg/m 2 IV day 1 every 3 weeks FAC fluorouracil 500 mg/m 2 IV every 3 weeks doxorubicin 50 mg/m 2 IV cyclophosphamide 500 mg/m 2 IV FE 100C fluorouracil 500 mg/m 2 IV day 1 every 3 weeks epirubicin 100 mg/m 2 IV day 1 cyclophosphamide 500 mg/m 2 IV day 1 Gemcitabine 800 mg/m 2 IV weekly every 3 weeks out of 4 Lapatinib capecitabine lapatinib capecitabine 1,250 mg po daily continuously during chemotherapy, then 1,500 mg 1,000 mg/m 2 po bid x 14 days every 3 weeks Myocet (liposomal doxorubicin) 75mg/m 2 IV every 3 weeks Myocet-cyclophosphamide myocet 60 mg/m 2 IV every 3 weeks cyclophosphamide 600 mg/m 2 IV

Paclitaxel-gemcitabine paclitaxel 175 mg/m 2 IV every 3 weeks gemcitabine 1,250 mg/m 2 IV days 1&8 Paclitaxel 175 mg/m 2 IV every 3 weeks Paclitaxel (weekly ) 80 mg/m 2 IV weekly continuously Paclitaxel with paclitaxel 175 mg/m 2 IV every 3 weeks Paclitaxel weekly with paclitaxel 80 mg/m 2 IV 4 mg/kg (1 st dose); followed by 2 mg/kg weekly continuously OR 8 mg/kg (1 st dose), followed by 6 mg/kg every 3 weeks Trastuzumab weekly 4 mg/kg (1 st dose); followed by 2 mg/kg weekly continuously Trastuzumab every 3 weeks Vinorelbine 25 mg/m 2 IV days 1,8 & 15 every 4 weeks Vinorelbine with vinorelbine 25 mg/m 2 IV days 1,8 & 15 every 4 weeks 4 mg/kg (1 st dose); followed by 2 mg/kg weekly continuously

Hormonal Treatments Tamoxifen 20 mg po once daily Anastrozole 1 mg po once daily Letrozole 2.5 mg po once daily Exemestane 25 mg po once daily Fulvestrant 500 mg IM Day 1, 15 and 29 then 500 mg IM monthly